Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PPBT | US
0.08
1.95%
Healthcare
Biotechnology
30/06/2024
17/10/2024
4.18
4.15
4.19
4.08
Purple Biotech Ltd. a clinical-stage company focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24 a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219 a small molecule that targets and inhibits insulin receptor substrate 1 and 2 and signal transducer and activator of transcription which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240 a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot Israel.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
104.3%1 month
88.2%3 months
84.3%6 months
94.4%-
-
0.22
0.01
0.01
-0.15
33.08
-
-19.62M
6.55M
6.55M
-
-
-
-
-44.67
0.39
0.90
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.72
Range1M
4.07
Range3M
7.49
Rel. volume
0.07
Price X volume
13.06K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
TFFP | TFFP | Biotechnology | 2.06 | 7.14M | -1.44% | n/a | 1.26% |
Portage Biotech Inc | PRTG | Biotechnology | 6.71 | 7.04M | 0.15% | 0.27 | 1.47% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.36 | 6.71M | -2.48% | n/a | 3.00% |
Aptose Biosciences Inc | APTO | Biotechnology | 0.36 | 6.52M | -2.17% | n/a | -37.59% |
CDIO | CDIO | Biotechnology | 0.2113 | 6.47M | -7.49% | n/a | 28.31% |
Adial Pharmaceuticals Inc | ADIL | Biotechnology | 0.9701 | 6.21M | -5.82% | n/a | 0.00% |
Hoth Therapeutics Inc | HOTH | Biotechnology | 0.9 | 6.21M | -3.26% | n/a | 0.44% |
Molecular Templates Inc | MTEM | Biotechnology | 0.93 | 6.16M | 186.07% | n/a | 155.07% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.052 | 6.14M | -13.33% | n/a | 461.91% |
NLS Pharmaceutics AG | NLSP | Biotechnology | 5.18 | 6.07M | 1.97% | n/a | -18.49% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.15 | 0.53 | Cheaper |
Ent. to Revenue | 33.08 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.22 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 84.28 | 72.92 | Par |
Debt to Equity | 0.01 | -1.24 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 6.55M | 3.78B | Emerging |